Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo Pharmaceuticals Solutions Inc.

Division of Endo International PLC
www.indevus.com

Latest From Endo Pharmaceuticals Solutions Inc.

Deal Watch: Lilly/Qiagen Tie-Up Leads Spate Of Cancer Diagnostic Partnerships

Bayer looks to augment Xofigo and its prostate cancer portfolio through development and commercialization pact with Orion around Phase III-ready asset once partnered with Endo. Meanwhile, Shire and arGEN-X expand a collaboration in which the latter’s antibody-discovery technologies are being used to discover potential candidates against targets chosen by Shire.

BioPharmaceutical Deals

Testosterone Petition From Public Citizen Eyes Industry Bias In Risk Findings

Seeking immediate relabeling of the products, advocacy group notes a meta-analysis found different CV risk depending on who funded the studies analyzed.

BioPharmaceutical North America

FDA rejects Endo low-T drug Aveed, again

After the US markets closed on 30 May, Endo Pharmaceuticals disclosed the US FDA had rejected the company's new drug application (NDA) for its long-acting testosterone undecanoate injection Aveed as a treatment for hypogonadism, or low testosterone, a condition that affects millions of American men and is associated with erectile dysfunction and decreased sexual desire, fatigue and loss of energy, depressed mood, osteoporosis and a diminishment in the physical characteristics of a man, such as decreased body hair.

Gynecology & Urology Orthopedics

REMS Can’t Help Endo’s Aveed – Won’t Address Unpredictable Safety Events, FDA Advisors Say

Without predictive factors to determine who is likely to get a severe post-injection reaction, FDA advisory committees say Endo’s proposed REMS for its long-acting testosterone is unlikely to allay safety concerns.

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Metabolic Disorders
  • Alias(es)
  • Interneuron Pharmaceuticals Inc.
  • Indevus Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Endo International PLC
  • Senior Management
  • Glenn L Cooper, MD, Chmn. & CEO
    Michael Rogers, EVP, CFO
    Nancy K Bryan, SVP, Sales & Mktg.
    Noah D Beerman, EVP, CBO
    Bobby Sandage, PhD, EVP, R&D & CSO
  • Contact Info
  • Endo Pharmaceuticals Solutions Inc.
    Phone: (781) 861-8444
    33 Hayden Ave.
    Lexington, MA 02421
    USA
UsernamePublicRestriction

Register